Peritoneal Lavage CEA mRNA Levels Predict Conversion Gastrectomy Outcomes after Induction Chemotherapy with Intraperitoneal Paclitaxel in Gastric Cancer Patients with Peritoneal Metastasis

2017 ◽  
Vol 24 (11) ◽  
pp. 3345-3352 ◽  
Author(s):  
Hironori Yamaguchi ◽  
Yumiko Satoh ◽  
Hironori Ishigami ◽  
Makiko Kurihara ◽  
Yutaka Yatomi ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Induction Chemotherapy ◽  
Peritoneal Metastasis ◽  
Peritoneal Lavage ◽  
Mrna Levels ◽  
Gastric Cancer Patients ◽  
Cea Mrna

scholarly journals A Proposal of a Practical and Optimal Prophylactic Strategy for Peritoneal Recurrence

2012 ◽  
Vol 2012 ◽  
pp. 1-7 ◽  
Author(s):  
Masafumi Kuramoto ◽  
Shinya Shimada ◽  
Satoshi Ikeshima ◽  
Akinobu Matsuo ◽  
Hiroshi Kuhara ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Surgical Technique ◽  
Cancer Cells ◽  
Cancer Patients ◽  
Peritoneal Metastasis ◽  
Therapeutic Strategy ◽  
Peritoneal Lavage ◽  
Randomized Study ◽  
Peritoneal Recurrence ◽  
Gastric Cancer Patients

Peritoneal metastasis, which often arises in patients with advanced gastric cancer, is well known as a miserable and ill-fated disease. Once peritoneal metastasis is formed, it is extremely difficult to defeat. We advocated EIPL (extensive intraoperative peritoneal lavage) as a useful and practical adjuvant surgical technique for those gastric cancer patients who are likely to suffer from peritoneal recurrence. In this paper, we review the effect of EIPL therapy on prevention of peritoneal recurrence on patients with peritoneal free cancer cells without overt peritoneal metastasis (CY+/P−) through the prospective randomized study, and we verified its potential as an optimal and standard prophylactic therapeutic strategy for peritoneal recurrence.

scholarly journals Prognostic significance of IL-17 mRNA expression in peritoneal lavage in gastric cancer patients who underwent curative resection

2013 ◽  
Vol 31 (2) ◽  
pp. 605-612 ◽  
Author(s):  
TAKESHI IIDA ◽  
MAKOTO IWAHASHI ◽  
MASAHIRO KATSUDA ◽  
KOICHIRO ISHIDA ◽  
MIKIHITO NAKAMORI ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Mrna Expression ◽  
Cancer Patients ◽  
Curative Resection ◽  
Peritoneal Lavage ◽  
Prognostic Significance ◽  
Gastric Cancer Patients

scholarly journals Survival Benefit of Traditional Chinese Herbal Medicine (A Herbal Formula for Invigorating Spleen) in Gastric Cancer Patients with Peritoneal Metastasis

2014 ◽  
Vol 2014 ◽  
pp. 1-6 ◽  
Author(s):  
Lu Zhao ◽  
Ai-Guang Zhao ◽  
Gang Zhao ◽  
Yan Xu ◽  
Xiao-Hong Zhu ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Herbal Medicine ◽  
Cancer Patients ◽  
Chinese Herbal Medicine ◽  
Peritoneal Metastasis ◽  
Herbal Formula ◽  
First Line ◽  
Traditional Chinese Herbal Medicine ◽  
Chinese Herbal ◽  
Gastric Cancer Patients

Objective.We evaluated the efficiency of traditional Chinese herbal medicine (a compound herbal formula for invigorating spleen) as a complementary and alternative therapy for gastric cancer patients with peritoneal metastasis.Methods.Between 2001 and 2012, 93 gastric cancer patients with peritoneal metastasis were enrolled in this study. The effect of traditional Chinese herbal medicine on their long-term outcome was investigated. Kaplan-Meier method was used to assess the difference in survival time, and Cox proportional hazards regression analysis was performed to identify independent prognostic factors.Result.First-line palliative chemotherapy plus traditional Chinese herbal medicine was performed in 47 patients and the other 46 patients received chemotherapy alone. The overall survival was different between patients with and without traditional Chinese herbal medicine (12.0 versus 10.5 months;P=0.046). According to the Cox proportional hazard model, first-line chemotherapy cycle (hazards ratio [HR] = 0.527; 95% CI = 0.323~0.860) and TCHM (hazards ratio [HR] = 0.644; 95% CI = 0.481~0.992) were selected as independent prognostic factors for survival.Conclusion.The results suggest that traditional Chinese herbal medicine could improve the prognosis of the gastric cancer patients with peritoneal metastasis.

scholarly journals Efficacy of Acupuncture and Moxibustion as a Subsequent Treatment after Second-Line Chemotherapy in Advanced Gastric Cancer

2020 ◽  
Vol 2020 ◽  
pp. 1-9
Author(s):  
Yong-jie Zhang ◽  
Qi Min ◽  
Ying Huang ◽  
Huai-dong Liu ◽  
Zi-yuan Zhu ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Advanced Gastric Cancer ◽  
Cancer Patients ◽  
Plasma Levels ◽  
Mrna Levels ◽  
Second Line ◽  
Second Line Chemotherapy ◽  
Acupuncture And Moxibustion ◽  
Gastric Cancer Patients ◽  
Line Chemotherapy

Objective. To explore whether acupuncture and moxibustion can prevent disease progression of advanced gastric cancer patients completing second-line chemotherapy and, if so, the related mechanism. Method. Progression-free survival (PFS) and overall survival (OS) were main outcome measures. The real-time quantitative PCR was used to detect the expression of genes including T-bet, IFN-γ, GATA3, and IL-4 in peripheral blood mononuclear cells (PBMCs). IL-4, IL-6, Ca199, CRP, and IFN-γ in plasma levels were checked. Results. 170 patients were randomly assigned in a 3 : 2 ratio to receive either acupuncture and moxibustion or sham acupuncture until progression. 135 patients were included in the primary analysis. Both PFS and OS in treatment group were proven to be better than control group. Acupuncture and moxibustion promoted typical Th1 cells drifting, as confirmed by increased T-bet/IFN-γ and decreased GATA3/IL-4 in mRNA levels from PBMCs, as well as upregulating IFN-γ and downregulating IL-4 in plasma levels. IL-6, Ca199, and CRP in plasma levels were also reduced by acupuncture and moxibustion. Conclusions. Acupuncture and moxibustion can prolong PFS and OS of advanced gastric cancer patients completing second-line chemotherapy by reversing Th1/Th2 shift and attenuating inflammatory responses.

scholarly journals Intraoperative peritoneal lavage cytology offers prognostic significance for gastric cancer patients with curative resection

2017 ◽  
Vol 108 (5) ◽  
pp. 978-986 ◽  
Author(s):  
Eiji Higaki ◽  
Shinya Yanagi ◽  
Naoto Gotohda ◽  
Takahiro Kinoshita ◽  
Takeshi Kuwata ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Curative Resection ◽  
Peritoneal Lavage ◽  
Prognostic Significance ◽  
Peritoneal Lavage Cytology ◽  
Lavage Cytology ◽  
Gastric Cancer Patients

Surgical outcomes for gastric cancer patients with intraperitoneal free cancer cell, but no macroscopic peritoneal metastasis

2011 ◽  
Vol 104 (5) ◽  
pp. 534-537 ◽  
Author(s):  
Hiroaki Saito ◽  
Kyoichi Kihara ◽  
Hirohiko Kuroda ◽  
Tomoyuki Matsunaga ◽  
Shigeru Tatebe ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Cancer Cell ◽  
Peritoneal Metastasis ◽  
Surgical Outcomes ◽  
Free Cancer Cell ◽  
Gastric Cancer Patients

Phase I study of biweekly intravenous paclitaxel plus intraperitoneal cisplatin and paclitaxel for gastric cancer with peritoneal metastasis.

2011 ◽  
Vol 29 (4_suppl) ◽  
pp. 139-139
Author(s):  
H. Ishigami ◽  
J. Kitayama ◽  
S. Kaisaki ◽  
H. Yamaguchi ◽  
H. Yamashita ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Phase I ◽  
Cancer Patients ◽  
Dose Level ◽  
Peritoneal Metastasis ◽  
Phase I Study ◽  
Level 1 ◽  
Grade 3 ◽  
Gastric Cancer Patients ◽  
Experienced Grade

139 Background: Intraperitoneal (IP) chemotherapy is promising for the treatment of gastric cancer with peritoneal metastasis. We previously verified the safety and efficacy of IP paclitaxel (PTX) combined with S-1 and intravenous (IV) PTX in phase I and phase II studies (Oncology. 2009; Ann Oncol. 2010). Secondly, we developed a new IP-containing chemotherapy regimen, IV PTX plus IP cisplatin (CDDP) and PTX, for patients who have failed S-1-based chemotherapy. We performed a phase I study to determine the maximum-tolerated dose (MTD) and recommended dose (RD) in gastric cancer patients. Methods: A total of 9 gastric cancer patients were enrolled who had shown progression of peritoneal metastasis after S-1-based chemotherapy. PTX was administered intravenously at a dose of 100 mg/m2 and intraperitoneally over 1 hour with an initial dose of 20 mg/m2 (level 1), stepped up to 30 or 40 mg/m2 depending on observed toxicity. CDDP was subsequently administered intraperitoneally at a dose of 30 mg/m2 over 24 hours after PTX infusion. PTX and CDDP were administered on days 1 and 15 in 4-week cycles. Results: At dose level 1, dose-limiting toxicities (DLTs) were observed in 2 of 3 patients. One patient experienced grade 4 leukopenia, and the other grade 3 vomiting. Because of higher toxicities than anticipated, the initial dose-escalation schedule was abandoned, and the doses of IV PTX and IP CDDP were reduced to 80 mg/m2 and 25 mg/m2, respectively, while keeping the dose of IP PTX at 20 mg/m2 (level 0). At dose level 0, one of the first 3 patients experienced grade 3 nausea, and an additional 3 patients experienced no DLTs. Consequently, the MTD and RD were determined to be dose level 1 and dose level 0, respectively. No patients experienced complications related to the peritoneal access device or IP infusion. Conclusions: Combination chemotherapy of IV PTX plus IP CDDP and PTX was shown to be a safe regimen that should be further explored in clinical trials. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document